This announcement is a separate document:
自愿披露关于GR1802注射液启动中、重度特应性皮炎适应症III期临床试验的公告
Announcement on voluntary disclosure of GR1802 injection on initiation of phase III clinical trials for moderate and severe atopic dermatitis indications
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.